Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Stenosis
- Sponsor
- NHS Greater Glasgow and Clyde
- Enrollment
- 40
- Locations
- 1
- Last Updated
- 19 years ago
Overview
Brief Summary
Antiplatelet therapy plays a key role in the prevention of complications related to coronary angioplasty and stenting (PCI) including procedure related myocardial damage. Aspirin and clopidogrel are now universally prescribed in patients undergoing these procedures. However, loading and maintenance doses have not been established and variation in individual response is emerging. New tests to assess the effects of these drugs are being developed but have yet to be incorporated into routine clinical practice. We will assess the effects of aspirin and clopidogrel in a consecutive series of patients undergoing angioplasty using new assays which can be carried out at the bedside. We will compare the results with alternative laboratory based tests and look for an association between the results, peri-procedural myocardial necrosis and subsequent cardiovascular events.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged 18-80 undergoing intended PCI for conventional indications. Informed written consent.
Exclusion Criteria
- •Administration of GPIIbIIIa therapy prior to PCI, Oral anticoagulation, ticlopidine, dipyridamole, NSAID therapy, Pregnancy, Troponin I \>0.2mcg/l on day of procedure, Chest pain in the 24 hrs prior to PCI. Anaemia (Hb\<10g/dl). Platelet Count \<150 or \>450 x10\^9/l, Personal or family history of bleeding disorder.
Outcomes
Primary Outcomes
Not specified